RxDoctor Payments Data

Natalie Cauthen, MD

Infectious Disease · West Columbia, SCNPI 1124095658

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Insmed, Inc. at 37.7% of the total. Reporting peaked in 2019 at $279 and has fallen 60.0% since, to $112 in 2023. That places this record below the midpoint for infectious disease clinicians in SC, where the typical reported total is $781.

$706in general payments, 2019–2025

Across 25 payments — averaging $28.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$266
  • Actelion Pharmaceuticals US, Inc.$124
  • Merck$74
  • Melinta Therapeutics, LLC$68
  • Tetraphase Pharmaceuticals, Inc.$43
  • Gilead$35
  • plus $97 from 5 others

What the payments were for

  • Food & beverage$68797%
  • Education$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$706 in reported general payments places this provider in the 45th percentile of 102 infectious disease providers in South Carolina.

See all infectious disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$40,230
Medicare patients
123
Services billed
464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Daptomycin11$20,511
ErtapenemErtapenem Sodium21$10,052

Paid to pharmacies, not to this prescriber.

Other infectious disease in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →